of the six patients in remission were ANA positive.
A clinical diagnosis of SLE could only be made in one patient (No 1), who has been reported in more detail elsewhere.6 She is the only patient in this study to have antibodies to DNA (dsDNA and ssDNA), SS-A, and nRNP, as well as having high titres of antibodies to cardiolipin and a strongly positive rheumatoid factor. Otherwise no clinical features of connective tissue disease were found apart from patient 5, who had had Still's disease as a child, and patient 13 who had had mild arthralgias for two to three years associated with antimitochondrial antibodies. The patient with nucleolar ANA staining had no features of scleroderma, but had breast carcinoma and diuretic induced gout.
Most of the ANA positive patients had a high ESR and three patients had raised immunoglobulin concentrations, two to three times the upper limit of normal (table 2). Significant titres of anticardiolipin antibodies were found in five patients, but there was no obvious relation with ANA positivity or activity of the porphyria. No clinical or immunological abnormalities were found in any of the patients with latent acute intermittent porphyria.
Further characterisation to ascertain whether the positive fluorescence was due to antihistone Clinical and laboratory indices suggesting a coexistent connective tissue disease were absent from all the patients with porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, and hereditary coproporphyria, apart from one patient with erythropoietic protoporphyria in whom an isolated speckled ANA was found on immunofluorescence. All of these patients had had clinically manifest disease, but none of the patients with variegate porphyria or hereditary coproporphyria had had a recent acute attack.
Discussion
The porphyrias have been described in association with a variety of autoimmune disorders.8 Two previous studies have failed to show an increased incidence of connective tissue disease in patients with porphyria cutanea tarda, though non-specific immunological abnormalities, such as raised ESR and immunoglobulins, were common.9 10 Although the association of SLE and acute porphyria has been described in several case reports, there have been no previous studies including patients with acute porphyria. The presence of ANAs in acute intermittent porphyria, which were not found in latent disease, might conceivably appear following cell damage after an acute porphyric attack. Our preliminary studies, however, suggest that induction of ANA is unlikely to be due solely to increased concentrations of b-aminolaevulinic acid or porphobilinogen. Whether the incidence of ANAs is also increased in the other types of acute porphyria will need more extensive study, as none of our patients with variegate porphyria and hereditary coproporphyria had had a recent acute attack.
This study suggests that the coexistence of SLE and porphyria in a patient is probably a chance occurrence. In some patients in whom the diagnosis of SLE is in doubt, particularly those with central nervous system involvement and negative tests for dsDNA, however, it may be of clinical value to consider porphyria as an alternative diagnosis and measure urinary porphyrins as a screening test.
